Archive Newsletter

1. 02.25.26 -- In Vivo's Biggest Threat: A Comparison To Older Models 2/25/2026
   02/25/26
2. 02.18.26 -- Reclaiming Efficiency In The mRNA Industry 2/18/2026
   02/18/26 Advancing RNA Newsletter
3. 02.04.26 -- Money In The Bank: Why 2025's Setbacks Were The Foundation RNA Needed 2/4/2026
   02/04/26 Advancing RNA Newsletter
4. 01.28.26 -- Manufacturing Complexities Stymie In Vivo Progress 1/28/2026
   01/28/26 Advancing RNA Newsletter
5. 01.21.26 -- Biology, Specificity, And The Rules Of RNA Business Strategy In 2026 1/21/2026
   01/21/26 Advancing RNA Newsletter
6. 01.07.26 -- Market Trends That Defined mRNA In 2025 1/7/2026
   01/07/26 Advancing RNA Newsletter
7. 12.23.25 -- Top 10 Of 2025 12/23/2025
   12/23/25 Advancing RNA Newsletter
8. 12.17.25 -- Critical Discussions Driving The mRNA Industry's Next Chapter 12/17/2025
   12/17/25 Advancing RNA Newsletter
9. 12.10.25 -- Global Trials And Oncology Insights 12/10/2025

   12/10/25 Advancing RNA Newsletter

10. 12.08.25 -- The Art of Phosphitylation – Innovating Efficiency In Oligonucleotide Synthesis 12/8/2025

    12/08/25 Advancing RNA Newsletter